A Phase I Clinical Trial Assessing the Safety and Pharmacokinetics of a Single Intravenous Administration of Methoxetamine Hydrochloride in Subjects With Mild to Moderate Renal Impairment Compared to Individuals With Normal Renal Function
Latest Information Update: 30 Dec 2024
Price :
$35 *
At a glance
- Drugs Methoxyetomidate (Primary)
- Indications Renal impairment
- Focus Pharmacokinetics
- Sponsors Ahon Pharmaceutical
- 30 Dec 2024 New trial record